Evidence map›Paper›PMID 37113037›Full record

Trial reportThe journal of allergy and clinical immunology. In practice2023

Retail Food Equivalents for Post-Oral Immunotherapy Dosing in the Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen Oral Immunotherapy in Food-Allergic Children and Adults (OUtMATCH) Clinical Trial.

Marion Groetch, Kim Mudd, Margaret Woch, Allison Schaible, Brianna E Gray, Denise C Babineau, J Andrew Bird, Stacie Jones, Edwin H Kim, Bruce J Lanser and 9 more

Open access · greenAbstract readClinical Trial
In one paragraph

Trial report in The journal of allergy and clinical immunology. In practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Trial
  2. Omalizumab for the Treatment of Multiple Food Allergies.The New England journal of medicine · 2024
    Trial
  3. Oral Food Challenges After Treatment With Omalizumab in the Clinical Setting.The journal of allergy and clinical immunology. In practice · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. The evolution of nutritional care in children with food allergies - With a focus on cow's milk allergy.Journal of human nutrition and dietetics : the official journal of the British Dietetic Association · 2025
    Review
  8. Article
  9. Recent advances in food allergen immunotherapy.Clinical and experimental pediatrics · 2024
    Article
  10. Review
  11. The Role of Biologics in the Treatment of Food Allergy.The journal of allergy and clinical immunology. In practice · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 12 institutions in 1 country.

Marion GroetchJaffe Food Allergy Institute, Division of Pediatric Allergy and Immunology, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: marion.groetch@mssm.edu.
Kim MuddDivision of Pediatric Allergy and Immunology, Johns Hopkins University School of Medicine, Baltimore, Md.
Margaret WochSean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, Calif.
Allison SchaibleJaffe Food Allergy Institute, Division of Pediatric Allergy and Immunology, Icahn School of Medicine at Mount Sinai, New York, NY.
Brianna E GrayTranslational and Clinical Research Centers, Massachusetts General Hospital, Boston, Mass.
Denise C BabineauRho, Inc, Durham, NC.
J Andrew BirdDivision of Allergy and Immunology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas.
Stacie JonesDivision of Allergy and Immunology, Department of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock, Ark.
Edwin H KimDivision of Pediatric Allergy and Immunology, Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, NC.
Bruce J LanserDepartment of Pediatrics, National Jewish Health, Denver, Colo.
Julian PoyserDivision of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
Nicole RogersRho, Inc, Durham, NC.
Wayne ShrefflerTranslational and Clinical Research Centers, Massachusetts General Hospital, Boston, Mass.
Scott SichererJaffe Food Allergy Institute, Division of Pediatric Allergy and Immunology, Icahn School of Medicine at Mount Sinai, New York, NY.
Amanda K Rudman SpergelDivision of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
Jonathan SpergelCenter for Pediatric Eosinophilic Diseases, Division of Allergy-Immunology, Children's Hospital of Philadelphia, Perelman School of Medicine at University of Pennsylvania, Philadelphia, Pa.
Brian P VickeryDivision of Allergy/Immunology at Emory University and Children's Healthcare of Atlanta, Atlanta, Ga.
R Sharon ChinthrajahSean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, Calif.
Robert WoodDivision of Pediatric Allergy and Immunology, Johns Hopkins University School of Medicine, Baltimore, Md.
Icahn School of Medicine at Mount Sinai · USMassachusetts General Hospital · USNational Institute of Allergy and Infectious Diseases · USStanford University · USEmory University · USJohns Hopkins Medicine · USJohns Hopkins University · USNational Jewish Health · USThe University of Texas Southwestern Medical Center · USUniversity of Arkansas for Medical Sciences · USUniversity of North Carolina at Chapel Hill · USUniversity of Pennsylvania · US

Funding

Transplantation GroupUM2AI117870 · NIAID · RHO FEDERAL SYSTEMS DIVISION, INC. · PI DAVID, GLORIA · 2015 to 2023
$208.1M
Harvard Clinical and Translational Science CenterUL1TR001102 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2013 to 2017
$106.2M
The Harvard Clinical and Translational Science CenterUL1TR002541 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2018 to 2022
$93.0M
HARVARD CLINICAL AND TRANSLATIONAL SCIENCE CENTER (UL1)UL1RR025758 · NCRR · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2008 to 2011
$91.4M
Treatment of Peanut Allergy with Intradermal Administration of ASP0892 (ARA-LAMP-vax): A Randomized, Double-Blind, Placebo-Controlled, Phase I/II StudyUM2AI130836 · NIAID · JOHNS HOPKINS UNIVERSITY · PI BURKS, A. WESLEY, WILLS-KARP, MARSHA · 2017 to 2023
$62.1M
QAQC Johns Hopkins Institute for Clinical and Translational ResearchUL1TR003098 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2019 to 2023
$57.7M
NIH Prior Approval Process ProfessionalUL1TR002535 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2018 to 2022
$51.1M
Re-Entry Supplement: Investigation of Oral Microbial Enzymes for the Detection and Treatment of Periodontal DiseaseUL1TR002489 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUSE, JOHN BERNARD, SHAHEEN, NICHOLAS J · 2018 to 2022
$48.6M
Harvard Clinical and Translational Science Center (UL1)UL1TR000170 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2012 to 2013
$31.4M
Expanding Translational Research in ArkansasUL1TR003107 · NCATS · UNIV OF ARKANSAS FOR MED SCIS · PI JAMES, LAURA P · 2019 to 2023
$21.6M
University of North Carolina Food Allergy InitiativeUM1AI130936 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KIM, EDWIN · 2017 to 2023
$2.0M
Mount Sinai's COFAR Clinical Research Unit and Clinical Trial (The "ADVANCE" Trial).UM1AI130570 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI SICHERER, SCOTT H · 2017 to 2023
$1.6M
NCATS NIH HHS UL1 TR000170NCATS NIH HHS UL1 TR001102NCATS NIH HHS UL1 TR002489NCATS NIH HHS UL1 TR002535NCATS NIH HHS UL1 TR002541NCATS NIH HHS UL1 TR003098NCATS NIH HHS UL1 TR003107NCRR NIH HHS UL1 RR025758NIAID NIH HHS U01 AI181962NIAID NIH HHS UM1 AI130570NIAID NIH HHS UM1 AI130780NIAID NIH HHS UM1 AI130781NIAID NIH HHS UM1 AI130838NIAID NIH HHS UM1 AI130934NIAID NIH HHS UM1 AI130936NIAID NIH HHS UM2 AI117870NIAID NIH HHS UM2 AI130836
6 · The paper itself

Abstract

backgroundPatients with food allergy may be advised to introduce specific foods into their diets, both to increase tolerance gradually and as next steps after completing oral immunotherapy or other therapeutic interventions. However, the safe use of retail foods depends on the ability to establish the specific allergen protein content of these foods.

objectiveTo develop a systematic approach to estimate the protein content of peanut, milk, egg, wheat, cashew, hazelnut, and walnut in a variety of retail food equivalents for each allergen and associated patient education materials.

methodWe created an algorithm that used a multistep process with information from product food labels, nutrient databases, independent weighing and measuring of foods, and information provided by manufacturers, including certificates of analysis, and e-mail communication to estimate the allergen protein content of multiple retail foods for each of seven allergens. Once a variety of retail food equivalents for each allergen and allergen serving size was determined, we developed participant education handouts, which were reviewed by study teams at 10 food allergy centers, the National Institute of Allergy and Infectious Diseases, and the Consortium for Food Allergy Research coordinating center. After 1 year of use, multiple queries were addressed and the retail food equivalents and educational materials were reviewed and edited.

resultsWe identified a variety of retail food equivalents for seven allergens at six serving sizes, and created 48 unique patient education materials.

conclusionOur results provide extensive guidance on a variety of retail equivalents for seven foods, and a method to estimate retail food protein equivalents systematically with ongoing reassessment.

Indexed as

Food HypersensitivityOmalizumabAdultAllergensChildDesensitization, ImmunologicHumansNutsAllergensOmalizumabAllergensConsortium for Food Allergy ResearchDietFood allergyNutritionOmalizumabOral immunotherapyOUtMATCHRetail food equivalents

Identifiers

PMID37113037
PMCPMC10147955
OpenAlexW4307458118

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.